View Older Stories View More Recent Stories

Feb 21, 2024 01:00AM Innate Pharma Announces Its Participation to Upcoming Investor Conference
Jan 12, 2024 01:00AM Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
Jan 4, 2024 05:11AM Innate Pharma (IPHA) Appoints Two New Executive Board Members
Jan 4, 2024 05:10AM Innate Pharma (IPHA) Announces FDA Lifts Partial Clinical Hold on Lacutamab
Jan 4, 2024 01:00AM Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
Jan 4, 2024 12:59AM Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
Dec 18, 2023 03:52AM Innate Pharma (IPHA) Announces CEO Resignation
Dec 18, 2023 01:00AM Innate Pharma Announces Leadership Change
Dec 11, 2023 03:43AM Innate Pharma (IPH) Reports Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101
Dec 11, 2023 01:00AM Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
Dec 10, 2023 01:00AM Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Nov 27, 2023 01:00AM Innate Pharma to Host Virtual KOL Event on Lacutamab
Nov 14, 2023 01:00AM Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
Nov 7, 2023 01:00AM Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
Nov 3, 2023 02:00AM Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
Oct 27, 2023 01:00AM Innate Pharma Announces Its Participation to Upcoming Investor Conferences
Oct 19, 2023 01:00AM Innate Pharma 2024 Financial Calendar
Oct 16, 2023 01:00AM Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
Oct 9, 2023 01:00AM Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
Oct 5, 2023 04:48AM Innate Pharma (IPHA) Provides Update on Lacutamab Clinical Program
Oct 5, 2023 01:00AM Innate Pharma Provides Update on Lacutamab Clinical Program
Sep 22, 2023 01:00AM Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 202
Aug 29, 2023 01:00AM Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
Aug 10, 2023 01:00AM Innate Pharma to Participate in Upcoming Investor Conference
Jul 11, 2023 01:00AM First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
Jul 7, 2023 01:00AM Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
Jun 26, 2023 01:00AM Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
Jun 26, 2023 01:00AM First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
Jun 16, 2023 06:05AM Innate Pharma (IPHA) Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study
Jun 16, 2023 01:00AM Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
Jun 12, 2023 01:00AM Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
Jun 10, 2023 01:00AM Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
Jun 8, 2023 01:00AM SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
Jun 8, 2023 01:00AM Innate Pharma: SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
Jun 7, 2023 01:00AM Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
May 26, 2023 01:00AM Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
May 23, 2023 01:00AM Innate Pharma to Participate in Upcoming Investor Conferences
May 15, 2023 01:00AM Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
May 12, 2023 04:00PM Outcome of Innate Pharma’s 2023 Annual General Meeting
May 10, 2023 01:00AM Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
May 9, 2023 01:00AM Number of shares and voting rights of Innate Pharma as of May 1, 2023
May 3, 2023 01:00AM Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
May 3, 2023 01:00AM Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
Apr 26, 2023 04:51PM Innate Pharma (IPHA) Establishes New At-The-Market Program on Nasdaq
Apr 26, 2023 04:50PM Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
Apr 26, 2023 04:50PM Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
Apr 21, 2023 01:00AM Innate Pharma to Participate in Upcoming Investor Conference
Apr 21, 2023 01:00AM Innate Pharma to Participate in Upcoming Investor Conference
Apr 18, 2023 01:00AM Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
Apr 18, 2023 01:00AM Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
View More Recent Stories View Older Stories